GlaxoSmithKlineE Past Earnings Performance

Past criteria checks 1/6

GlaxoSmithKlineE's earnings have been declining at an average annual rate of -21.2%, while the Pharmaceuticals industry saw earnings growing at 5.8% annually. Revenues have been growing at an average rate of 6.2% per year. GlaxoSmithKlineE's return on equity is 2%, and it has net margins of 1.5%.

Key information

-21.2%

Earnings growth rate

-23.3%

EPS growth rate

Pharmaceuticals Industry Growth9.8%
Revenue growth rate6.2%
Return on equity2.0%
Net Margin1.5%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How GlaxoSmithKlineE makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

CASE:BIOC Revenue, expenses and earnings (EGP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 242,493384910
31 Dec 232,240603480
30 Sep 232,131-1392850
30 Jun 232,107-1173460
31 Mar 231,914-1203600
31 Dec 221,823-1143380
30 Sep 222,0991933780
30 Jun 221,9591933880
31 Mar 222,0422094330
31 Dec 211,8121554400
30 Sep 211,549-404000
30 Jun 211,627-1043930
31 Mar 211,699-423950
31 Dec 201,993284950
30 Sep 201,9301774990
30 Jun 201,8782305030
31 Mar 201,7641755080
31 Dec 191,7041434740
30 Sep 191,690-134670
30 Jun 191,645194730
31 Mar 191,630324550
31 Dec 181,623504420
30 Sep 181,563-34390
30 Jun 181,556594100
31 Mar 181,5081064080
31 Dec 171,4531023720
30 Sep 171,3501623160
30 Jun 171,2381353040
31 Mar 171,207872670
31 Dec 161,166-42460
30 Sep 161,1162702090
30 Jun 161,0941381780
31 Mar 161,080731860
31 Dec 151,010691830
30 Sep 151,031-961700
30 Jun 151,054-441760
31 Mar 151,031-191650
31 Dec 141,062641710
30 Sep 141,077661970
30 Jun 141,061731920
31 Mar 141,051741980
31 Dec 131,041771920
30 Sep 13982831870
30 Jun 13959511870

Quality Earnings: BIOC has a large one-off loss of EGP146.9M impacting its last 12 months of financial results to 31st March, 2024.

Growing Profit Margin: BIOC became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BIOC's earnings have declined by 21.2% per year over the past 5 years.

Accelerating Growth: BIOC has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: BIOC has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (27.9%).


Return on Equity

High ROE: BIOC's Return on Equity (2%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.